IL157031A0 - Thyroid receptor ligands - Google Patents
Thyroid receptor ligandsInfo
- Publication number
- IL157031A0 IL157031A0 IL15703102A IL15703102A IL157031A0 IL 157031 A0 IL157031 A0 IL 157031A0 IL 15703102 A IL15703102 A IL 15703102A IL 15703102 A IL15703102 A IL 15703102A IL 157031 A0 IL157031 A0 IL 157031A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor ligands
- thyroid receptor
- thyroid
- ligands
- receptor
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 102000004217 thyroid hormone receptors Human genes 0.000 title 1
- 108090000721 thyroid hormone receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0103175A GB0103175D0 (en) | 2001-02-08 | 2001-02-08 | Novel compounds |
| GB0105234A GB0105234D0 (en) | 2001-03-02 | 2001-03-02 | Novel compounds |
| PCT/EP2002/000957 WO2002062780A2 (en) | 2001-02-08 | 2002-01-30 | Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL157031A0 true IL157031A0 (en) | 2004-02-08 |
Family
ID=26245703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15703102A IL157031A0 (en) | 2001-02-08 | 2002-01-30 | Thyroid receptor ligands |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7144909B2 (https=) |
| EP (1) | EP1358175A2 (https=) |
| JP (1) | JP2004531479A (https=) |
| KR (1) | KR20030072396A (https=) |
| AU (1) | AU2002237298B2 (https=) |
| CA (1) | CA2435820A1 (https=) |
| IL (1) | IL157031A0 (https=) |
| WO (1) | WO2002062780A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219022D0 (en) * | 2002-08-15 | 2002-09-25 | Karobio Ab | Novel thyromimetic compounds |
| TW200504021A (en) | 2003-01-24 | 2005-02-01 | Bristol Myers Squibb Co | Substituted anilide ligands for the thyroid receptor |
| CN1882327A (zh) | 2003-11-19 | 2006-12-20 | 症变治疗公司 | 含磷的新的拟甲状腺素药 |
| WO2006128058A2 (en) | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
| US20070082907A1 (en) * | 2003-11-25 | 2007-04-12 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
| RU2007111760A (ru) * | 2004-09-01 | 2008-10-10 | Трастиз Оф Бостон Юниверсити (Us) | Способ лечения гиперпролиферативного кожного нарушения |
| WO2006128056A2 (en) * | 2005-05-26 | 2006-11-30 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| GB0513692D0 (en) * | 2005-07-04 | 2005-08-10 | Karobio Ab | Novel pharmaceutical compositions |
| PL1919878T3 (pl) * | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| GB0608724D0 (en) * | 2006-05-03 | 2006-06-14 | Karobio Ab | Novel Pharmaceutical Compositions |
| GB0610322D0 (en) * | 2006-05-24 | 2006-07-05 | Karobio Ab | Novel pharmaceutical compositions |
| US7960567B2 (en) * | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
| RU2469725C2 (ru) * | 2010-07-01 | 2012-12-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тверская государственная медицинская академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО "Тверская ГМА" Минздравсоцразвития России) | Способ предоперационной подготовки больных тиреотоксикозом |
| CN102718718B (zh) * | 2012-05-31 | 2014-09-24 | 绍兴文理学院 | 一种3,5-二溴-4-（5-苯并咪唑氧基）苯乙酸的制备方法 |
| CA3044059A1 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| US11707472B2 (en) | 2017-06-05 | 2023-07-25 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| ES3053674T3 (en) | 2018-03-22 | 2026-01-23 | Viking Therapeutics Inc | Crystalline forms and methods of producing crystalline forms of a compound |
| WO2020117962A1 (en) | 2018-12-05 | 2020-06-11 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9226532D0 (en) * | 1992-12-21 | 1993-02-17 | Smithkline Beecham Plc | Compounds |
| US6472387B1 (en) * | 1996-10-07 | 2002-10-29 | Eli Lilly And Company | Methods of using compounds as neuro-protective agents |
| EA001713B1 (ru) * | 1996-10-07 | 2001-08-27 | Эли Лилли Энд Компани | Соединения, полезные для использования в качестве нейрозащитных средств |
| GB9713739D0 (en) | 1997-06-27 | 1997-09-03 | Karobio Ab | Thyroid receptor ligands |
| GB9828442D0 (en) | 1998-12-24 | 1999-02-17 | Karobio Ab | Novel thyroid receptor ligands and method II |
| WO2001070687A1 (de) | 2000-03-23 | 2001-09-27 | Bayer Aktiengesellschaft | Indole zur behandlung von krankheiten die mit schilddrüsenhormonen behandeln werden können |
| WO2002051805A1 (de) | 2000-12-27 | 2002-07-04 | Bayer Aktiengesellschaft | Indol-derivate |
-
2002
- 2002-01-30 EP EP02703589A patent/EP1358175A2/en not_active Withdrawn
- 2002-01-30 IL IL15703102A patent/IL157031A0/xx unknown
- 2002-01-30 AU AU2002237298A patent/AU2002237298B2/en not_active Ceased
- 2002-01-30 CA CA002435820A patent/CA2435820A1/en not_active Abandoned
- 2002-01-30 KR KR10-2003-7010172A patent/KR20030072396A/ko not_active Withdrawn
- 2002-01-30 US US10/470,878 patent/US7144909B2/en not_active Expired - Fee Related
- 2002-01-30 JP JP2002563134A patent/JP2004531479A/ja active Pending
- 2002-01-30 WO PCT/EP2002/000957 patent/WO2002062780A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CA2435820A1 (en) | 2002-08-15 |
| EP1358175A2 (en) | 2003-11-05 |
| KR20030072396A (ko) | 2003-09-13 |
| WO2002062780A3 (en) | 2002-09-26 |
| US20040116387A1 (en) | 2004-06-17 |
| JP2004531479A (ja) | 2004-10-14 |
| AU2002237298B2 (en) | 2006-08-03 |
| US7144909B2 (en) | 2006-12-05 |
| WO2002062780A2 (en) | 2002-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU3092901A (en) | Aniline-derived ligands for the thyroid receptor | |
| AU2003225305A8 (en) | Pyridine-based thyroid receptor ligands | |
| HUP0104666A3 (en) | Thyroid receptor ligands | |
| IL157969A0 (en) | Melanocortin receptor ligands | |
| AU8066701A (en) | Capsaicin receptor ligands | |
| IL161439A0 (en) | Cannabinoid receptor ligands | |
| IL156829A0 (en) | Cannabinoid receptor ligands | |
| GB2387913B (en) | Interface detector | |
| EP1432444A4 (en) | ANTI-BETA ANTIBODIES | |
| GB0101996D0 (en) | Organtic compounds | |
| IL157031A0 (en) | Thyroid receptor ligands | |
| IL162242A0 (en) | Azaindolylalkylamine derivatives as5-hydroxytryptamine-6 ligands | |
| AU2003272511A8 (en) | Cd44-binding ligands | |
| GB0108102D0 (en) | Compounds | |
| GB0012054D0 (en) | Ligands | |
| GB0226374D0 (en) | Ligands | |
| GB0115841D0 (en) | Ligand | |
| GB0230202D0 (en) | Ligand | |
| GB0105098D0 (en) | Compounds | |
| GB9920046D0 (en) | Novel receptor/ligand | |
| GB0106434D0 (en) | Novel estrogwen receptor ligands and methods II | |
| GB0110662D0 (en) | Receptor | |
| GB0114929D0 (en) | Receptor | |
| GB0111959D0 (en) | Receptor | |
| GB0125183D0 (en) | Receptor |